BioCryst Pharmaceuticals Inc
BCRXHealthcare|Drug Manufacturers - Specialty & Generic|USA
$10.45
-0.27 (-2.52%)
Clinical Trials (57)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06842823 A Study of Navenibart in Participants With Hereditary Angioedema | Hereditary Angioedema (HAE) | P3 | Active | 157 | RCT, Double-blind | navenibart, Placebo |
| NCT05453968 Berotralstat Treatment in Children With Hereditary Angioedema | Hereditary Angioedema, Pediatric | P3 | Active | 29 | Open-label | Berotralstat |
| NCT06539507 A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 | Netherton Syndrome | P1 | Recruiting | 78 | RCT, Double-blind | BCX17725, Placebo |
| NCT02665351 Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections | Influenza | P2P3 | Completed | 16 | RCT, Open-label | Peramivir |
| NCT03485911 Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE | Hereditary Angioedema, HAE | P3 | Completed | 121 | RCT, Double-blind | BCX7353 capsules, Placebo oral capsule |
| NCT03873116 Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan | Hereditary Angioedema, HAE | P3 | Completed | 19 | RCT, Double-blind | BCX7353 capsules, BCX7353 capsules, Placebo oral capsule |
| NCT02635724 Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza | Influenza | P3 | Completed | 74 | Open-label | Peramivir |
| NCT02303626 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks | Hereditary Angioedema, HAE | P2P3 | Completed | 110 | RCT, Double-blind | BCX4161, Placebo |
| NCT00486980 Intramuscular Peramivir for the Treatment of Uncomplicated Influenza | Influenza | P3 | Withdrawn | — | RCT, Double-blind | Peramivir 150mg, Peramivir 300mg |
| NCT00957996 Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza | Seasonal Influenza, Cough | P3 | Completed | 234 | RCT, Open-label | Peramivir, Peramivir |
| NCT02369159 Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza | Influenza | P3 | Completed | 137 | RCT, Open-label | Peramivir, Oseltamivir |
| NCT01224795 A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza. | Influenza | P3 | Withdrawn | — | RCT, Double-blind | Peramivir, Placebo Comparator |
| NCT03472040 A Long Term Safety Study of BCX7353 in Hereditary Angioedema | Hereditary Angioedema, HAE | P2P3 | Completed | 387 | Open-label | BCX7353 |
| NCT02670720 Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema | Hereditary Angioedema, HAE | P3 | Terminated | 6 | Open-label | avoralstat |
| NCT04933721 Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies | Hereditary Angioedema, HAE | P3 | By Invite | 139 | Open-label | berotralstat |
| NCT00610935 Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza | Influenza | P3 | Terminated | 82 | RCT, Double-blind | Peramivir, Placebo |
| NCT00958776 A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza | Cough, Sore Throat | P3 | Terminated | 405 | RCT, Double-blind | Peramivir+SOC, Placebo+SOC |
| NCT05116787 BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy | Paroxysmal Nocturnal Hemoglobinuria (PNH) | P2 | Terminated | 12 | RCT, Double-blind | Placebo, BCX9930 monotherapy |
| NCT01129648 Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout | Gout | P2 | Completed | 87 | RCT, Double-blind | Placebo, Allopurinol, Allopurinol, Allopurinol, BCX4208, Allopurinol, Allopurinol, Allopurinol, BCX4208, Allopurinol, Allopurinol, Allopurinol, BCX4208, Allopurinol, Allopurinol, Allopurinol, BCX4208 |
| NCT00453999 Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza | Influenza | P2 | Completed | 137 | RCT, Double-blind | Peramivir 200 mg, Peramivir 400 mg, Oseltamivir |
| NCT02870972 Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema | Hereditary Angioedema (HAE) | P2 | Completed | 75 | RCT, Double-blind | BCX7353, Placebo |
| NCT04702568 A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Paroxysmal Nocturnal Hemoglobinuria, PNH | P2 | Terminated | 19 | Open-label | BCX9930, Eculizumab, Ravulizumab |
| NCT04330534 First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH | Paroxysmal Nocturnal Hemoglobinuria | P1P2 | Completed | 168 | Open-label | BCX9930, Placebo |
| NCT00705406 A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza | Acute, Uncomplicated Human Influenza | P2 | Completed | 405 | RCT, Double-blind | Peramivir, Placebo |
| NCT00035022 Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas | Leukemia, Lymphocytic, Lymphoma | P1P2 | Completed | 71 | Open-label | BCX-1777 |
| NCT00419263 Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza. | Influenza | P2 | Completed | 344 | RCT, Double-blind | Peramivir 150 mg, Peramivir 300 mg, Placebo |
| NCT00419081 Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens | Leukemia, Lymphoma | P2 | Terminated | 100 | Open-label | Forodesine Hydrochloride Sterile Solution, 5 mg/mL, Forodesine Hydrochloride Capsules (100 mg) |
| NCT00985127 Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout | Gout | P2 | Completed | 99 | RCT, Double-blind | placebo, BCX4208 |
| NCT05116774 BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy | Paroxysmal Nocturnal Hemoglobinuria (PNH) | P2 | Terminated | 12 | RCT, Open-label | Eculizumab, Ravulizumab, BCX9930 |
| NCT05741346 Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | P2 | Terminated | 28 | Open-label | BCX9930 |
| NCT00061880 BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma | Lymphoma | P1P2 | Completed | — | Open-label | forodesine hydrochloride |
| NCT00640523 Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL) | Chronic Lymphocytic Leukemia (CLL) | P2 | Completed | 23 | Open-label | forodesine HCl |
| NCT01407874 A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency | Gout, Hyperuricemia | P2 | Completed | 20 | RCT, Double-blind | Placebo, Ulodesine (BCX4208) 5 mg, Ulodesine (BCX4208) 10 mg |
| NCT01265264 Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol | Gout, Hyperuricemia | P2 | Completed | 279 | RCT, Double-blind | ulodesine, Placebo |
| NCT01984788 Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE | Hereditary Angioedema | P2 | Completed | 24 | RCT, Double-blind | BCX4161, Placebo |
| NCT00501735 Forodesine in the Treatment of Cutaneous T-Cell Lymphoma | Cutaneous T-cell Lymphoma (CTCL), | P2 | Completed | 144 | Open-label | Forodesine 200 mg |
| NCT00289549 Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL) | Leukemia, Lymphocytic, Chronic | P2 | Completed | 8 | Open-label | forodesine hydrochloride (BCX-1777) |
| NCT00289562 Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | P1P2 | Completed | 20 | Open-label | forodesine hydrochloride (BCX-1777) |
| NCT00095381 Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia | Leukemia, T-Cell | P2 | Completed | 20 | Open-label | forodesine hydrochloride (BCX-1777) |
| NCT03240133 Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema | Hereditary Angioedema (HAE) | P2 | Completed | 58 | RCT, Double-blind | BCX7353, Placebo |
| NCT05162066 Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) | Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy | P2 | Terminated | 2 | Open-label | BCX9930 |
| NCT06100900 Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) | Paroxysmal Nocturnal Hemoglobinuria | P1 | Completed | 8 | Open-label | BCX10013 |
| NCT03136237 A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions | Hereditary Angioedema | P1 | Completed | 54 | Open-label | BCX7353, Digoxin, BCX7353 + digoxin, Rosuvastatin, rosuvastatin + BCX7353, Cyclosporine + BCX7353 |
| NCT02319772 A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430 | Filovirus Infections, Ebola Virus Infection | P1 | Completed | 94 | RCT, Double-blind | BCX4430, Placebo |
| NCT02218294 Study to Determine How BCX4161 is Metabolized and Eliminated by the Body | Hereditary Angioedema | P1 | Completed | 7 | Open-label | BCX4161 |
| NCT00098332 Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma | Lymphoma | P1 | Completed | — | Open-label | forodesine hydrochloride |
| NCT02819102 An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates | Hereditary Angioedema | P1 | Completed | 20 | Open-label | BCX7353 and probes |
| NCT00073944 BCX-1777 in Treating Patients With Refractory Cancer | Cancer | P1 | Completed | — | Open-label | forodesine hydrochloride |
| NCT07228559 A Study of Avoralstat In Participants With Diabetic Macular Edema | Diabetic Macular Edema (DME) | P1 | Terminated | 3 | Open-label | avoralstat |
| NCT03202784 A Relative Bioavailability Study of Two Formulations of BCX7353 | Hereditary Angioedema | P1 | Completed | 24 | RCT, Open-label | BCX7353 |
| NCT02125162 A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161 | Hereditary Angioedema | P1 | Completed | 28 | RCT, Open-label | BCX4161 |
| NCT03891420 A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19 | COVID-19, Yellow Fever | P1 | Terminated | 24 | RCT, Double-blind | Galidesivir, Placebo |
| NCT00002237 A Study of Peldesine (BCX-34) in HIV-Infected Patients | HIV Infections | P1 | Completed | — | — | Peldesine |
| NCT03800173 A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430 | Marburg Virus Disease | P1 | Completed | 32 | RCT, Double-blind | galidesivir, placebo |
| NCT02448264 First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers | Hereditary Angioedema | P1 | Completed | 122 | RCT, Double-blind | BCX7353, Placebo to match BCX7353 |
| NCT04428632 Oral Berotralstat Expanded Access Program | Hereditary Angioedema, HAE | APPROVED_FOR_MARKETING | — | — | Berotralstat | |
| NCT01146353 Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy | Influenza, Renal Failure | Withdrawn | — | — | — |